Fireside Chats have become one of the more popular program elements to our global events. Fireside chats feature candid Q&As between biopharma CEOs, who discuss recent company successes, what keeps the C-suite up at night, and where the industry’s leading companies are headed in 2014.

West Moving East

Tuesday, November 12, 2013
11:00 a.m. - 11:55 a.m.
Room 402 A&B
Moderator: E. Allan Gabor, Managing Director, Merck Serono China

	Susan Herbert, PhD Head of Global BD & Strategy Merck KGaA
	Annalisa Jenkins, MBBS, MRCP Executive VP and Head of Global Research and Development Merck KGaA

New Face of Traditional Medicine

Tuesday, November 12, 2013
3:00 p.m. - 3:55 p.m.
Room 403
Moderator: Helen Chen, Director & Partner, L.E.K. Consulting 

Dr. Henry Sun Vice President, Tasly Holding Group CEO, Tasly Pharmaceuticals, Inc.

Innovation/Dealmaking in China from a Small Company Perspective

Wednesday, November 13, 2013
9:30 a.m. - 10:25 a.m.
Room 405
Moderator: Alan F. Eisenberg, Vice President, Federal Government Relations, Celgene Corp.

Wang Yinxiang, PhD CEO and Chief Scientific Officer Zhejiang Beta Pharma

Additional One-on-One Dialogues

Tuesday, November 12, 2013
1:30 p.m. - 2:25 p.m.
​Room 403
Moderator: C. Simone Fishburn, Senior Editor, SciBX at BioCentury Publications

Wang Xiaodong, PhD Director and Investigator National Institute of Biological Sciences (NIBS)

Business Focused Sessions

• China Private Health Care Industry
Current wave of private hospitals, building from the ground up. Challenge in how to get patients and physicians. Pharma angle: how to partner with these hospitals? Private hospitals can only grow with the success of private health insurance. These two markets are dependent on one another to succeed. What’s the role of the private sector? How will it/can it evolve in the next couple of years? Deloitte/Monitor to provide 10 mins presentation upfront to show facts, figures and key trends.
• New VC Models in China
Innovative drug development programs in China are growing rapidly, which--combined with the ongoing reform of CFDA towards better performance and faster time to market--theoretically shall turn the country into a new El Dorado for biotech venture capitalists and private equity investors. Reality is, however, quite far away from this idyllic picture: among other factors, under-performing local stock markets and relatively scarce trade sale opportunities result in many VC/PE facing only limited exit options. Shall investors simply adjust their expectations while waiting for the environment to mature, or are there China-specific investment/exit models to explore?
• State of Capital Markets in China
For the unprepared investor, capital markets in China can easily challenge usual habits and expectations. Unique market sensitivity factors, among which non-convertible currency, collide to hinder market efficiency, especially in the biopharma sector where success stories are rarer than offers to go private (Simcere Pharmaceuticals undoubtedly being the most prominent recent example). This panel will explore the realm of the state of the capital markets in China through the prism of the biotech industry, assess the current and future attractiveness of local IPOs, and carry the debate towards a global perspective to provide both biotechs and investors with applicable insights.
• Opportunities from EDL expansion  
Recently, China’s Ministry of Health released the widely anticipated expansion of the essential drug to list (EDL) to 520 drugs (from 307) to cover diseases such as cancers. With the market share of EDLS drugs continue to grow, opportunities exist for both western pharma and Chinese TCM companies. This panel will explore the expanded EDL list how companies can best leverage this opportunity.

Scientific Focused Sessions

• Cancer Epigenetics and Emerging Therapies
Ten years after the sequencing of the human genome, the use of epigenetics in developing targeted cancer treatments is rapidly growing. What are recent discoveries in epigenetic abnormalities and what are the implications for cancer treatment? What emerging therapies are on the forefront of this new and cutting-edge research?
• Treating NSCLC in China 
Lung cancer is the leading cause of death in the world and prevalence of NSCLC in China is no exception. Prominent oncologists from both the clinic and the bench will provide their insights on this growing treatment market. How do branded Western drugs fare against the Chinese competitors? Which drugs currently dominate the Chinese NSCLC market and how will the market continue to grow?
• Traditional Chinese Medicine
China has used Traditional Chinese Medicine (TCM) for centuries and still comprises a substantial portion of the Chinese healthcare industry. How are these medicines used in China and what are the opportunities for TCM outside of China?
• Diabetes Dx and Treatment in China
As the prevalence of diabetes continues to rise in China, the country plans to enact regulations to screen high-risk populations, necessitating the availability of more treatments across the country. Several pharmacos have already increased their distribution and manufacturing capabilities of these new medications. What’s in the diagnostics pipeline for identifying these at-risk populations? What is currently the standard of care and how will that change in the next few years?
• Respiratory Disease in China—Treatment and Prevention
According to the World Health Organization (WHO), chronic respiratory disease is the 2nd leading cause of death in China. Chronic obstructive pulmonary disease (COPD) is rapidly increasing as a public health concern in the country, necessitating proper education, diagnosis and treatment. This panel will explore current treatment paradigms, both in TCM and western medicine, in addition to current research and prevention mechanisms.
• Vaccines 
Hand, foot, and mouth disease continues to represent a significant unmet public health need and economic burden in China, as well as several other Asian countries. Flu also continues to be rampant in China. What vaccines are being used and what vaccines are in late stage development that can be leveraged in the at-risk populations in China?
• Rare Diseases in China  
The establishment of China’s first national organization against rare diseases (China Rare Diseases Prevention & Treatment Alliance) reaffirms the country’s commitment to innovative health care research. China is actively promoting the regulation of rare diseases and orphan drugs. This panel will focus on the research and development of orphan drugs in China.

Policy Focused Sessions

• Building a World-Class Innovative Therapeutic Biologics Industry in China
BIO and R&D Based Pharmaceutical Association Committee (RDPAC) have commissioned a multi-year study on best practices in building an innovative therapeutic biologics industry in China, exploring success and failures in other markets. Key recommendations are made with the intention of providing a foundation for revision on the next five-year plan as it relates to biotechnology, one of China’s seven Strategic Emerging Industries (SEIs)
• China’s New Party Leadership, Implications for Central Planning and Regulation
This past March, China went through a historic leadership transition. As the new president, Xi Jinping, takes the helm and ministries like the China Food & Drug Administration (CFDA) are elevated in importance, what are the implications for the biotechnology industry in China?
• Looking Forward: 13th Five-Year Plan & Its Investment in Innovation
As China’s 12th Five-Year Plan concludes in 2015, the country begins to lay the groundwork for the 13th Five-Year Plan for 2016-2020. This panel will explore lessons learned, areas of strength, areas for improvement, and where industry can support central planners moving forward.

Please find an initial list of companies confirmed to present at the BIO® Convention in China. If you're interested in presenting, please submit an application, or email Jennifer Fernandez at jfernandez(at)bio.org.

Company	News & Information	Presentation Date, Time (ET), and Location
	3SBio Website  |  News	Wednesday, 11/13 9:00 am Room 407
	Ampsource Inc.	Wednesday, 11/13 9:00 am Room 406
	AnewPharma Company Ltd	Tuesday, 11/12 10:30 am Room 407
	Apexigen Website  |  News	Tuesday, 11/12 4:00 pm Room 406
	Aslan Pharmaceuticals Pte Ltd Website  |  News	Wednesday, 11/13 2:00 pm Room 407
	AstraZeneca Website  |  News	Tuesday, 11/12 4:30 pm Room 406
	BeiGene Ltd. Website  |  News	Tuesday, 11/12 10:30 am Room 406
	Biomiga Diagnostics Website  |  News	Tuesday, 11/12 1:00 pm Room 407
	Boehringer-Ingelheim Website  |  News	Wednesday, 11/13 1:30 pm Room 406
	Bristol-Myers Squibb Website  |  News	Tuesday, 11/12 11:00 am Room 406
	C5-6 Technologies Website  |  News	Tuesday, 11/12 11:00 am Room 407
	China Grand Enterprises Website  |  News	Wednesday, 11/13 1:00 pm Room 407
	College Hill Life Sciences Website  |  News	Tuesday, 11/12 5:00 pm Room 407
	Genentech Website  |  News	Tuesday, 11/12 2:00 pm Room 406
	Genfit Website  |  News	Wednesday, 11/13 1:30 pm Room 407
	gIcare pharma Website  |  News	Wednesday, 11/13 11:30 am Room 406
	HitGen Ltd. Website  |  News	Wednesday, 11/13 9:30 am Room 407
	Horizon Discovery Website  |  News	Tuesday, 11/12 3:00 pm Room 407
	Hua Medicine Website | News	Tuesday, 11/12 2:00 pm Room 407
	Hutchison MediPharma Website | News	Wednesday, 11/13 10:00 am Room 406
	Johnson & Johnson Innovation Center Website  |  News	Tuesday, 11/12 11:30 am Room 406
	Luqa Pharmaceuticals Website  |  News	Tuesday, 11/12 11:30 am Room 407
	Merck Millipore Website  |  News	Wednesday, 11/13 9:30 am Room 406
	Merck Serono Website  |  News	Tuesday, 11/12 1:00 pm Room 406
	Microsens Biophage	Tuesday, 11/12 3:30 pm Room 407
	MSD Website  |  News	Wednesday, 11/13 2:00 pm Room 406
	NNE Pharmaplan Website |  News	Tuesday, 11/12 1:30 pm Room 407
	PharmaEssentia Corp. Website |  News	Tuesday, 11/12 3:30 pm Room 406
	Phynova Group Ltd Website |  News	Tuesday, 11/12 5:00 pm Room 406
	Public Health England Website  |  News	Tuesday, 11/12 4:00 pm Room 407
	Roche Website  |  News	Tuesday, 11/12 1:30 pm Room 406
	SciClone Pharmaceuticals Website  |  News	Wednesday, 11/13 11:00 am Room 407
	Shanghai Biotechnology Corporation Website |  News	Wednesday, 11/13 10:00 am Room 407
	Sundia MediTech Website  |  News	Tuesday, 11/12 10:30 am Room 407
	Tianjin Crystec Pharmaceutical Technology Co. Website  |  News	Tuesday, 11/12 3:00 pm Room 406
	Venner Shipley Intellectual Property LLP Website  |  News	Tuesday, 11/12 4:30 pm Room 407

Wednesday, October 24, 4:30-5:30pm

The R&D based Pharmaceutical Association Committee (RDPAC) and BIO have commissioned a study with the support of the Boston Consulting Group (BCG) to assess multiple policy levers which have the potential to accelerate the development of the therapeutic biologics sector in China and the integration of the Chinese therapeutic biologics industry into global R&D and healthcare markets. The therapeutic biologics industry holds significant promise for China to achieve breakthrough innovation and to address largely unmet medical needs in diseases such as diabetes, cancer, and immunological impairment. As biotechnology has been designated as one of China’s seven strategic emerging industries by the government in the current 12^th five-year plan, this study is in the process of formulating a set of recommendations which balance the immediate next steps for the industry with long-term action plans.

Moderator:

• Joseph Damond, Senior Vice President, International Affairs, BIO

Panelists:

• James Cai, Medical Director of Shanghai Roche Pharmaceutical Co.
• Joseph Cho, Managing Director, RDPAC
• Shi Luwen, PhD, Professor, Peking University School of Pharmaceutical Sciences
• Yu Mingde, President, China Pharmaceutical Enterprises Association

Who's Who

Joseph Damond Senior Vice President, International Affairs, BIO As Senior Vice President for International Affairs at the Biotechnology Industry Organization (BIO), Mr. Damond is responsible for developing and implementing the industry association’s program of international advocacy and outreach, including the areas of trade policy and foreign government relations. Prior to taking his position at BIO, Mr. Damond was Vice President for International Government Relations in Pfizer’s Washington Office from 2006-2011. In that capacity he was responsible for managing and coordinating Pfizer’s international trade issues with the Administration and Congress. Prior to his appointment at Pfizer in 2006, Mr. Damond was with the Pharmaceutical Research and Manufacturers of America (PhRMA) for five years.  As PhRMA’s Deputy Vice President for International Affairs, he was responsible for managing PhRMA’s programs with respect to market access barriers that affect the research-based pharmaceutical industry, as well as managing PhRMA’s Asia and Japan programs. Before coming to PhRMA, Mr. Damond spent 12 years as a trade negotiator at the Office of the United States Trade Representative, where his last assignment, from 1999-2001, was as Deputy Assistant U.S. Trade Representative for Asia and Pacific/APEC Affairs.  During this time, he was also chief negotiator of the historic U.S.-Vietnam Bilateral Trade agreement, completed in July 2000.  Prior to his time at USTR, Mr. Damond also spent four years at the U.S. Commerce Department, working on bilateral and multilateral trade negotiations. Mr. Damond received his Master’s degree from Princeton University’s Woodrow Wilson School of Public and International Affairs in 1985, and his undergraduate degree magna cum laude from Georgetown University, School of Foreign Service, in 1983.

Wednesday, October 24th, 4:30-5:30pm

China is actively investing in biotechnology development through many different avenues. Hear a panel of experts explain the advantages of operating in China and engaging in cross-border collaborations, and learn how Chinese and Western biopharma companies can gain access to meaningful capital.

Moderator:

• TBD

Panelist:

• Samantha Du, PhD, Managing Director, Sequoia Capital
• Alan Hu, Healthcare Fund Partner, Deloitte
• Dan Junguo, PhD, Chendgu University of Traditional Chinese Medicine
• Sun Wansong, PhD, Director of Investment Promotion, Secretary of the CPC, Clinical Medicine, Ministry of Commerce, People's Republic of China
• Yu Yanfei, Section Chief, Fudding Construction Section of Bio City of Wu Han Guang Gu Cluster

Who's Who